GMAB
Genmab A/s
A Danish biotechnology company that designs antibody-based medicines to treat cancer and other serious diseases. Its best-known drug is Darzalex, a treatment for the blood cancer multiple myeloma that it co-developed with Johnson & Johnson's Janssen division. Founded in 1999 in Copenhagen by two researchers, it takes its name from a blend of "gen" for genetics and "mab," the standard abbreviation for monoclonal antibody—the very molecules it engineers.
ADRUnderlying: GMABCUSIP: 372303206HealthcareDK1 holder
Sponsored ADR
Total Value
$3.23M
Total Shares
107.9K
Net Share Change
+733
Activity
1 buying
Investor
Value
Shares
Weight
Change
